Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

Expert review finds no evidence that corticosteroids slow ALS progression

Original source

Glucocorticoid CorticosteroidsALSUntangled · 29 August 2022 (opens in a new tab)

An ALS Untangled expert review found that preclinical and clinical trials have not shown a clinical benefit from corticosteroids in amyotrophic lateral sclerosis (ALS). The review does not recommend corticosteroids to slow ALS progression at this time. Some people with ALS have reported improved weakness, but these reports are difficult to interpret.

Why this matters

This means corticosteroids should not be viewed as an established treatment for slowing ALS. They can cause side effects, with greater risks at higher doses or with prolonged use. Further research into immune-system modulation in ALS is ongoing, but this review does not show a treatment benefit today.

Limitations and context

This is an independent expert review, not a new clinical trial or primary research study. The review does not provide a single study size or treatment result, and the reported individual improvements came from self-reports with uncertain diagnosis, limited clinical data, and differences in drug type and dose. Treatment decisions should be discussed with a clinician.

Summarised by Compass 9 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?